Massimo Breccia

Summary

Affiliation: University of Rome La Sapienza
Country: Italy

Publications

  1. request reprint
    Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris M, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007;21:79-83 pubmed
    ..Our findings suggest that, in APL patients consistent biologic features of leukemia cells may predict increased risk of developing thrombosis. ..
  2. Breccia M, Lo Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031-43 pubmed publisher
    ..The results of ongoing randomized studies should better define the role of ATO in front-line therapy. ..
  3. Breccia M, Molica M, Zacheo I, Serrao A, Alimena G. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol. 2015;94:393-7 pubmed publisher
    ..001). SCORE chart evaluation at disease baseline could be a valid tool to identify patients at high risk of atherosclerotic events during nilotinib treatment. ..
  4. request reprint
    Breccia M, Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets. 2009;9:21-8 pubmed
    ..This review will discuss the underlying mechanisms of imatinib-resistance and new strategies to avoid and overcome this phenomenon. ..
  5. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055-9 pubmed publisher
    ..This study suggests a higher level of satisfaction with more information received but the need of improving communication about possible future treatment free remission. ..
  6. Breccia M, Voso M, Aloe Spiriti M, Fenu S, Maurillo L, Buccisano F, et al. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. Ann Hematol. 2015;94:771-7 pubmed publisher
    ..The aims of this review are to provide all available information relating clinical and hematologic changes after chelation therapy and to discuss potential mechanisms involved in such responses. ..
  7. Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, et al. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. Leuk Lymphoma. 2010;51:783-8 pubmed publisher
  8. Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sora F, et al. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Ann Hematol. 2018;97:1577-1580 pubmed publisher
    ..Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance. ..
  9. Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D adda M, et al. Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leuk Res. 2016;40:24-9 pubmed publisher
    ..Present results, achieved in a large cohort of patients treated outside clinical trials, further confirm the efficacy and safety of dasatinib as firstline treatment in CML. ..

More Information

Publications25

  1. request reprint
    Breccia M, Mengarelli A, Mancini M, Biondo F, Gentilini F, Latagliata R, et al. Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res. 2005;29:749-54 pubmed
    ..001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome. ..
  2. request reprint
    Breccia M, Cannella L, Nanni M, Stefanizzi C, Alimena G. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 2007;118:162-4 pubmed
  3. Breccia M, Alimena G. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf. 2010;9:713-21 pubmed publisher
    ..Literature evidences support the fact that with adequate management and monitoring of patients with predisposing factors, pleural effusions can be easily managed. ..
  4. Breccia M, Foà R. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. Curr Oncol Rep. 2018;20:23 pubmed publisher
    ..We hereby review the current information based on the available published data and discuss the current suggestions on how to move TFR into the clinical practice. ..
  5. request reprint
    Breccia M, Morano S, D Andrea M, Russo E, D Elia G, Alimena G. Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management. Eur J Haematol. 2005;75:396-400 pubmed
    ..Furthermore, we suggest the need of routine screening for thrombophilic state in young women affected by PV. ..
  6. Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38:1392-8 pubmed publisher
    ..Aim of present review is to report metabolic changes and potential mechanisms involved in the pathogenesis related to imatinib, second (nilotinib and dasatinib) and third generation (bosutinib and ponatinib) TKIs. ..
  7. Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, et al. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Ann Hematol. 2012;91:1345-9 pubmed publisher
    ..In conclusion, the oral iron chelator deferasirox is effective and safe when used in MDS patients with transfusion requirement, also if administered concomitantly with other drugs. ..
  8. Breccia M, Graffigna G, Galimberti S, Iurlo A, Pungolino E, Pizzuti M, et al. Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Support Care Cancer. 2016;24:4487-93 pubmed publisher
    ..Narrative medicine, in association to quantitative analysis, can help physicians to understand needs of their patients in order to improve communication. ..
  9. Breccia M, Molica M, Colafigli G, Massaro F, Alimena G. Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. Leuk Res. 2016;48:20-5 pubmed publisher
    ..Aim of this review is to summarize all evidences reported on the significance of EMR and how this evaluation changed our perspectives and modified our therapeutic strategies. ..
  10. Breccia M, Pregno P, Spallarossa P, Arboscello E, Ciceri F, Giorgi M, et al. Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Ann Hematol. 2017;96:549-558 pubmed publisher
    ..It summarises suggestions that may help to improve the therapeutic index of ponatinib, primarily in the settings of chronic-phase chronic myeloid leukaemia. ..
  11. Breccia M, Arboscello E, Bellodi A, Colafigli G, Molica M, Bergamaschi M, et al. Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. Crit Rev Oncol Hematol. 2016;107:190-198 pubmed publisher
    ..Several national haematologist and cardiologist reviewed the literature, analysed levels of evidence for each topic and, after extensive discussions presented their proposals based on current international guidelines. ..
  12. Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, et al. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Ann Hematol. 2017;96:387-391 pubmed publisher
  13. Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, et al. Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Ann Hematol. 2018;97:745-754 pubmed publisher
    ..There is a need for specific methods to assess frailty in patients with MPNs, particularly the context of effective new treatment options, such as TKIs and ruxolitinib. ..
  14. request reprint
    Breccia M, Alimena G. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL. Curr Drug Targets. 2009;10:530-6 pubmed
    ..We here review the development of nilotinib and the efficacy data in phase II and front-line trials. ..
  15. Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci A, Carmosino I, et al. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma. 2008;49:2328-32 pubmed publisher
  16. request reprint
    Breccia M, Mandelli F, Petti M, D Andrea M, Pescarmona E, Pileri S, et al. Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 2004;28:1165-9 pubmed